ArticleFrontiers in pharmacology2020
The Expiry of Humira
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
4.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Pooled it
- Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review.Frontiers in public health · 2024Pooled it
- Patients' Perceptions of Biosimilars: A Systematic Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Pooled it
- Efficacy, safety and immunogenicity of etanercept biosimilarsFrontiers in pharmacology · 2023Pooled it
- Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.Journal of Crohn's & colitis · 2023Trial
- Adalimumab biosimilars compared to originator: impact on uveitic macular edema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.Acta dermato-venereologica · 2025Article
- Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends.Recent advances in inflammation & allergy drug discovery · 2025Review
- A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability.Frontiers in pharmacology · 2025Article
- Adalimumab around the world: comparative analysis of products characteristics and patient support systems.Therapeutic advances in gastroenterology · 2025Review
- Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians.PharmacoEconomics - open · 2024Article
- Role of supply chain intermediaries in steering hospital product choice: Group Purchasing Organizations and biosimilars.Health affairs scholar · 2024Article
- Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis.Ocular immunology and inflammation · 2024Article
- Article
- Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 20 institutions in 24 countries.
Evelien MoorkensDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Brian GodmanStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Isabelle HuysDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Iris HoxhaDepartment of Pharmacy, University of Medicine Tirana, Tirana, Albania.
Admir MalajDepartment of Pharmacy, University of Medicine Tirana, Tirana, Albania.
Simon KeuerleberAustrian Social Insurance, Vienna, Austria.
Silvia StockingerAustrian Social Insurance, Vienna, Austria.
Sarah MörtenhuberAustrian Social Insurance, Vienna, Austria.
Maria DimitrovaFaculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Konstantin TachkovFaculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Luka VončinaFaculty of Health Studies, University of Rijeka, Rijeka, Croatia.
Vera Vlahović PalčevskiFaculty of Health Studies, University of Rijeka, Rijeka, Croatia.
Gnosia AchniotouHealth Insurance Organization (HIO), Nicosia, Cyprus.
Juraj SlabýState Institute for Drug Control, Prague, Czechia.
Leona PopelkováState Institute for Drug Control, Prague, Czechia.
Kateřina KohoutováState Institute for Drug Control, Prague, Czechia.
Dorthe BartelsAmgros, Copenhagen, Denmark.
Ott LaiusState Agency of Medicines, Tartu, Estonia.
Jaana E MartikainenPharmaceuticals Pricing Board, Ministry of Social Affairs and Health, Helsinki, Finland.
Gisbert W SelkeAOK Research Institute (WIdO), Berlin, Germany.
Vasileios KourafalosNational Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece.
Einar MagnússonMinistry of Welfare, Reykjavik, Iceland.
Rannveig EinarsdóttirThe National University Hospital of Iceland, Reykjavik, Iceland.
Roisín AdamsSt James's Hospital, Dublin, Ireland.
Roberta JoppiClinical Research and Drug Evaluation Unit, Local Health Authority of Verona, Verona, Italy.
Eleonora AllocatiMario Negri Institute for Pharmacological Research (IRCCS), Milan, Italy.
Arianit JakupiUBT - Higher Education Institute, Prishtina, Kosovo.
Anita ViksnaDepartment of Medicines and Medical Devices, The National Health Service, Riga, Latvia.
Ieva Greičiūtė-KuprijanovMinistry of Health of the Republic of Lithuania, Vilnius, Lithuania.
Patricia Vella BonannoStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Vincent SuttorpErasmus University Medical Center, Rotterdam, Netherlands.
Øyvind MelienReviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, Norway.
Robert PliskoHTA Consulting, Cracow, Poland.
Ileana MardarePublic Health and Management Department, Faculty of Medicine, "Carol Davila", University of Medicine and Pharmacy Bucharest, Bucharest, Romania.
Dmitry MeshkovV. A. Trapeznikov Institute of Control Sciences of Russian Academy of Sciences, Moscow, Russia.
Tanja NovakovicZEM Solutions, Belgrade, Serbia.
Jurij FürstHealth Insurance Institute, Ljubljana, Slovenia.
Corinne ZaraDrug Area, Catalan Health Service, Barcelona, Spain.
Vanda Marković-PekovićDepartment of Social Pharmacy and Pharmacy Practice, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
Nataša GrubišaHealth Insurance Fund, Banja Luka, Bosnia and Herzegovina.
Gustaf BefritsStockholm County Council, Stockholm, Sweden.
Robert PuckettNHS Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Arnold G VultoDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
State Institute for Drug Control · CZErasmus MC · NLKU Leuven · BEMedical University of Sofia · BGUniversity of Medicine Tirana · ALUniversity of Rijeka · HRAgència de Qualitat i Avaluació Sanitàries de Catalunya · ESCarol Davila University of Medicine and Pharmacy · ROCRE Consulting (Poland) · PLHealth Insurance Institute of Slovenia · SIMario Negri Institute for Pharmacological Research · ITMinistry of Social Affairs and Health · FIMinistry of Welfare · ISNational Public Health Organization · GRNational University Hospital of Iceland · ISNicosia General Hospital · CYNorwegian Institute of Public Health · NOQueen Elizabeth University Hospital · GBSefako Makgatho Health Sciences University · ZASt. James's Hospital · IE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
adalimumabbiosimilarscompetitionEuropehealth policyHumiraprices
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.